Login Register Cart 0
Research Article

ZQMT对小鼠实验性年龄相关性黄斑变性的抑制作用

卷 19, 期 6, 2019

页: [434 - 442] 页: 9

弟呕挨: 10.2174/1566524019666190425195706

价格: $65

摘要

背景：年龄相关性黄斑变性（AMD）是一种进行性和不可逆转的眼病。抗血管内皮生长因子（VEGF）疗法彻底改变了新生血管性AMD的治疗方法。然而，这种治疗的费用非常高。 方法：我们使用中药ZQMT作为AMD的替代治疗方案。我们采用两种分别模拟干性和湿性AMD的体内动物模型来评估ZQMT治疗AMD相关视网膜病变的疗效。通过眼底照相从第1周至第8周评估Crb1rd8小鼠中与AMD相关的视网膜病变。通过荧光素血管造影术和组织病理学评估激光诱导的脉络膜新血管形成（CNV）。 结果：ZQMT增加了在体外培养或直接从用ZQMT处理的动物分离的鼠CD4 + T细胞中的CX3CR1表达。我们还进行了体外和体内研究，以证实ZQMT没有明显的毒性作用。 ZQMT减轻了Crb1rd8和CNV模型中与AMD相关的视网膜病变。 Crb1rd8小鼠中CCL2和CX3CR1的消耗消除了ZQMT的功效，表明CCL2和/或CX3CR1可能是ZQMT在小鼠中治疗AMD相关视网膜病变的机制的基础。 结论：总之，我们的研究支持中药ZQMT在AMD中的保护作用。

关键词: 年龄相关性黄斑变性，中药，CX3CR1，ZQMT，CCL2，VEGF。

« Previous Next »
[1]
Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet 2018; 392(10153): 1147-59.
[2]
Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet Glob Health 2014; 2(2): e106-16.
[3]
Kauppinen A, Paterno JJ, Blasiak J, Salminen A, Kaarniranta K. Inflammation and its role in age-related macular degeneration. Cell Mol Life Sci 2016; 73(9): 1765-86.
[4]
Parmeggiani F, Sorrentino FS, Romano MR, et al. Mechanism of inflammation in age-related macular degeneration: an up-to-date on genetic landmarks. Mediators Inflamm 2013; 2013: 435607.
[5]
Raoul W, Auvynet C, Camelo S, et al. CCL2/CCR2 and CX3CL1/CX3CR1 chemokine axes and their possible involvement in age-related macular degeneration. J Neuroinflammation 2010; 7: 87.
[6]
Falk MK, Singh A, Faber C, Nissen MH, Hviid T, Sorensen TL. CX3CL1/CX3CR1 and CCL2/CCR2 chemokine/ chemokine receptor complex in patients with AMD. PLoS One 2014; 9(12): e112473.
[7]
Combadiere C, Feumi C, Raoul W, et al. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J Clin Invest 2007; 117(10): 2920-8.
[8]
Despriet DD, Bergen AA, Merriam JE, et al. Comprehensive analysis of the candidate genes CCL2, CCR2, and TLR4 in age-related macular degeneration. Invest Ophthalmol Vis Sci 2008; 49(1): 364-71.
[9]
Mattapallil MJ, Wawrousek EF, Chan CC, et al. The Rd8 mutation of the Crb1 gene is present in vendor lines of C57BL/6N mice and embryonic stem cells, and confounds ocular induced mutant phenotypes. Invest Ophthalmol Vis Sci 2012; 53(6): 2921-7.
[10]
Zhang J, Tuo J, Cao X, Shen D, Li W, Chan CC. Early degeneration of photoreceptor synapse in Ccl2/Cx3cr1-deficient mice on Crb1(rd8) background. Synapse 2013; 67(8): 515-31.
[11]
Chen M, Hombrebueno JR, Luo C, et al. Age- and light-dependent development of localised retinal atrophy in CCL2(-/-)CX3CR1(GFP/GFP) mice. PLoS One 2013; 8(4): e61381.
[12]
Imai T, Hieshima K, Haskell C, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997; 91(4): 521-30.
[13]
Ma W, Wong WT. Aging changes in retinal microglia and their relevance to age-related retinal disease. Adv Exp Med Biol 2016; 854: 73-8.
[14]
Shaw AC, Goldstein DR, Montgomery RR. Age-dependent dysregulation of innate immunity. Nat Rev Immunol 2013; 13(12): 875-87.
[15]
Tuo J, Bojanowski CM, Zhou M, et al. Murine ccl2/cx3cr1 deficiency results in retinal lesions mimicking human age-related macular degeneration. Invest Ophthalmol Vis Sci 2007; 48(8): 3827-36.
[16]
Song L. The observation of clinical therapeutic efficacy of ZQMT on non-ischemic retinal vein occlusion. Chin J Clin Rat Drug Use 2014; 7(36): 138-9.
[17]
Jin M, Zhang Y, Pan L, Dou R, Nussenblatt RB, Wei L. The Chinese medicine formula HB01 reduces choroidal neovascularization by regulating the expression of vascular endothelial growth factor. J Transl Med 2012; 10: 118.
[18]
Zhang W, Li Y, Lin J, et al. Comparison of hematoxylin-eosin staining and methyl violet staining for displaying ghost cells. Eye Sci 2013; 28(3): 140-3.
[19]
Ambati J, Fowler BJ. Mechanisms of age-related macular degeneration. Neuron 2012; 75(1): 26-39.
[20]
Ding X, Patel M, Chan CC. Molecular pathology of age-related macular degeneration. Prog Retin Eye Res 2009; 28(1): 1-18.
[21]
Bowes Rickman C, Farsiu S, Toth CA, Klingeborn M. Dry age-related macular degeneration: mechanisms, therapeutic targets, and imaging. Invest Ophthalmol Vis Sci 2013; 54(14): ORSF68-80.
[22]
Prasad PS, Schwartz SD, Hubschman JP. Age-related macular degeneration: current and novel therapies. Maturitas 2010; 66(1): 46-50.
[23]
Leung E, Landa G. Update on current and future novel therapies for dry age-related macular degeneration. Expert Rev Clin Pharmacol 2013; 6(5): 565-79.
[24]
Pieramici DJ, Rabena MD. Anti-VEGF therapy: Comparison of current and future agents. Eye (Lond) 2008; 22(10): 1330-6.
[25]
Hussain RM, Hariprasad SM, Ciulla TA. Treatment burden in neovascular AMD: Visual acuity outcomes are associated with anti-VEGF injection frequency. Ophthalmic Surg Lasers Imaging Retina 2017; 48(10): 780-4.
[26]
Liu Y, Yin HJ, Shi DZ, Chen KJ. Chinese herb and formulas for promoting blood circulation and removing blood stasis and antiplatelet therapies. Evid Based Complement Alternat Med 2012; 2012: 184503.
[27]
Duan L, Xiong X, Hu J, Liu Y, Li J, Wang J. Panax notoginseng saponins for treating coronary artery disease: A functional and mechanistic overview. Front Pharmacol 2017; 8: 702.
[28]
Melo PA, do Nascimento MC, Mors WB, Suarez-Kurtz G. Inhibition of the myotoxic and hemorrhagic activities of crotalid venoms by Eclipta prostrata (Asteraceae) extracts and constituents. Toxicon 1994; 32(5): 595-603.
[29]
Wang S, Cunnusamy K. Pharmaceutical composition for treating macular degeneration (WO2012079419). Expert Opin Ther Pat 2013; 23(2): 269-72.
[30]
Jin M, Dai H, Zhang X, et al. A traditional chinese patent medicine ZQMT for neovascular age- related macular degeneration: A multicenter randomized clinical trial. Curr Mol Med 2018; 18(9): 622-9.
[31]
Luhmann UF, Lange CA, Robbie S, et al. Differential modulation of retinal degeneration by Ccl2 and Cx3cr1 chemokine signalling. PLoS One 2012; 7(4): e35551.
[32]
Ambati J, Anand A, Fernandez S, et al. An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat Med 2003; 9(11): 1390-7.

Rights & Permissions Print Cite
Article Metrics
65
11
2
© 2024 Bentham Science Publishers | Privacy Policy